Transdermal nitroglycerin in patients with severe pre‐eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices

Gonçalves

Ultrasound Obstet Gynecol

et al. 2016

Self Cite

Section: Discussionsupporting

confidence: 91%

“…Glyceryl trinitrate (nitroglycerin, GTN) produces NO through a biotransformation pathway. A previous study on GTN showed improvement in Doppler indices and maternal blood pressure. One of its limitations is the development of tolerance, which can be reduced by intermittent administration.…”

Section: Introductionmentioning

confidence: 99%

Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices

Gonçalves

Ultrasound Obstet Gynecol

et al. 2016

Self Cite

Expert Review of Clinical Pharmacology

“…NO precursors are represented by L-arginine [35]. Evidence for their role in the prevention and treatment of PE is now emerging, yet deriving from small clinical studies [36,37]. Thus, further research is needed in this field before clinical recommendations could be given.…”

Section: Nitric Oxide Donors and Precursorsmentioning

confidence: 97%

Upcoming drugs for the treatment of preeclampsia in pregnant women

Ornaghi

Paidas

2014

Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2 - 8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic approaches are still severely limited. Ongoing lines of research indicate some potential novel therapeutic options, targeting the etiopathogenic pathways and, thus, offering hope for effective pharmacologic interventions to be available in the near future. In this editorial, we will give an updated overview of Preeclampsia pathogenesis and promising emerging therapeutic options.

“…They reported an increase of the blood low in the uterine and umbilical arteries. However, further investigation is needed for their efect reducing the incidence of PE [33].…”

Section: No Pathwaymentioning

confidence: 99%

Pharmacological Opportunities for Prevention of Preeclampsia

García-Benavides¹,

Molina²,

Vega³

et al. 2017

Obstetrics

Preeclampsia (PE) is a disorder that occurs during pregnancy, it has an estimated worldwide prevalence of 5-8%, being one of the leading causes of maternal and perinatal morbidity and mortality. Currently, diferent diagnostic criteria exist, however, due to its complexity; the clinical presentation that makes up this syndrome could make its presence unclear. The pathophysiology of PE has been recently postulated and divided into three processes: inadequate uterine remodeling, placental dysfunction and maternal endothelial dysfunction. Despite the advances in the treatment of PE, the outcome of the medical interventions has failed to decrease the morbidity and mortality of this disease. The main reason might be the multifactorial origin of pathogenic processes that lead to the development of PE. That is why treatment is focused on the prevention of PE in patients that might present the risk before developing it late in pregnancy. The knowledge of the pathophysiological factors that trigger the processes that culminate in the presentation of PE, is key for prevention of this disease. However, the origin of these processes is poorly understood. It may be atributed to the ethical considerations that come with the study of these population of patients compared with the study of nonpregnant women.